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Abstract 
This primer focuses on a recently diagnosed tick‑borne allergic disease known as the alpha‑Gal syndrome (AGS). Tick 
bites induce in humans high levels of IgE antibodies against the carbohydrate Galα1‑3Galβ1‑(3)4GlcNAc‑R (α‑Gal) 
present on tick salivary glycoproteins and tissues of non‑catarrhine mammals, leading to the AGS in some individu‑
als. This immune response evolved as a conflict and cooperation between ticks and human hosts including their gut 
microbiota. The conflict is characterized by the AGS that mediate delayed anaphylaxis to red meat consumption and 
certain drugs such as cetuximab, and immediate anaphylaxis to tick bites. The cooperation is supported by the capac‑
ity of anti‑α‑Gal IgM and IgG antibody response to protect against pathogens with α‑Gal on their surface. Despite 
the growing diagnosis of AGS in all world continents, many questions remain to be elucidated on the tick proteins 
and immune mechanisms triggering this syndrome, and the protective response against pathogen infection elicited 
by anti‑α‑Gal antibodies. The answer to these questions will provide information for the evaluation of risks, diagnosis 
and prevention of the AGS, and the possibility of using the carbohydrate α‑Gal to develop vaccines for the control of 
major infectious diseases.
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What is the alpha‑Gal syndrome (AGS)?
The main objective of our research is the characteriza-
tion of vector-host-pathogen molecular interactions, and 
translating this basic biological information into new 
interventions for the diagnosis, prevention and control 
of vector-borne diseases [1–3] (see also video at https ://
youtu .be/DhbBj QSuLY k). Arthropod vector-borne dis-
eases are a growing problem worldwide, and ticks are 
only second to mosquitoes as vectors of human diseases 
and the most important vectors in animals [4–6].
The alpha-Gal syndrome (AGS) is triggered by IgE anti-
body response against the carbohydrate Galα1-3Galβ1-
(3)4GlcNAc-R (α-Gal), which is present in glycoproteins 
from tick saliva and tissues of non-catarrhine mammals 
[7–13] (Additional file 1: Figure S1). In 2007, van Nunen 
et  al. [7] first described the association between tick 
bites and the development of mammalian meat allergy. 
In 2009, Commins et al. [11] confirmed this association 
and discovered the epitope likely responsible for such 
allergic reactions, (α-Gal). Old World monkeys, apes 
and humans evolved with the inactivation of the α-1,3-
galactosyltransferase (GalT) gene, which resulted in the 
recognition of α-Gal to produce high antibody titers 
against this antigen [12] (Additional file  1: Figure S1). 
Tick bites induce high levels of anti-α-Gal IgE antibodies 
in humans that mediate delayed anaphylaxis to red meat 
consumption, and immediate anaphylaxis to tick bites, 
xenotransplantation and certain drugs such as cetuximab 
[13, 14].
The AGS is becoming a global problem with increasing 
prevalence in all continents, and several tick species have 
been implicated in these disorders [10, 15] (Additional 
file  1: Figure S1). Remarkably, most of the patients that 
become allergic, had tolerated red meat for many years 
before being sensitized by tick bites [10]. This finding sug-
gests that while IgG and IgM antibody responses to α-Gal 
produced by some bacteria of the gut microbiota are ben-
eficial as they protect against infection by pathogens such 
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as malaria parasites and tuberculosis mycobacteria, anti-
α-Gal IgE antibodies induced by tick bites break the oral 
tolerance to food allergens and induce anaphylactic reac-
tions to tick α-Gal-containing salivary proteins [7–15].
Why only some individuals develop the AGS 
in response to tick bites?
Tick saliva is a complex mixture of pharmacologically 
active compounds with a role in tick attachment cement 
and feeding, pathogen transmission, and the inhibition 
of host defensive mechanisms through immunomodula-
tory, anti-hemostatic and anti-inflammatory molecules 
[16–26]. Transcriptomics, proteomics and metabolomics 
studies of tick salivary glands, saliva and cement discov-
ered clusters of functionally related proteins with pro-
tease inhibitors being the most abundant group of tick 
salivary secreted proteins in Ixodes scapularis [16, 18, 
20–26]. The genes coding for some of these proteins are 
usually expressed sequentially throughout tick feeding, 
bringing up the question of whether this phenomenon 
could be a form of antigenic variation [16]. Tick saliva 
modulates host immunity towards a T helper 2 (Th-2) 
response and suppresses inflammatory responses [27], 
thus deviating the host immune response to profiles that 
are less damaging to the feeding tick and pathogen trans-
mission. Apart from proteins with immunomodulatory 
activity, ticks also produce non-protein molecules such 
as prostaglandin E2  (PGE2), which is synthesized in the 
tick salivary glands and secreted via the saliva into the 
feeding lesion [26, 28].
Humans do not synthesize the carbohydrate α-Gal, and 
therefore all the sources of α-Gal for the human body are 
from non-human origin [9, 11–13, 29]. Consequently, 
humans can develop a potent immune response against 
this carbohydrate [9, 11–13, 29]. Recently, we demon-
strated that ticks synthesize α-Gal with functional GalTs 
with implications of this protein modification in tick 
feeding and Anaplasma phagocytophilum infection [30]. 
Considering these facts, evidence supports a role for 
α-Gal-containing tick salivary proteins in the develop-
ment of the AGS, possibly in conjunction with other tick 
salivary components [9, 11–13, 29]. At least two possible 
mechanisms explain the production in humans of anti-α-
Gal IgE antibodies after tick bites (Additional file 1: Fig-
ure S1). The first mechanism is supported by our current 
understanding of the host immune modulation by tick 
saliva, and proposes that α-Gal on tick salivary proteins 
interacts with antigen-presenting cells (APC) and B lym-
phocytes in the context of Th2 cell-mediated immunity 
induced by tick saliva. Basophils and released histamine 
have been implicated in IgE-mediated acquired pro-
tective immunity to tick infestations and chronic itch 
[31–35]. This mechanism leads to the elevation of the 
anti-α-Gal IgE response [16, 28]. The second mechanism 
needs to be demonstrated, and is based on the possibility 
that tick saliva contains factors that induce class switch 
recombination (CSR) to anti-α-Gal IgE producing B cells 
of pre-existing B cell clones producing anti-α-Gal IgM 
and/or IgG antibodies [28].
Tick salivary proteins with or without α-Gal modifica-
tions that may be involved in triggering the AGS have not 
been identified, but some α-Gal-containing proteins have 
been shown to be recognized by patients with anaphy-
lactic reaction to tick bite and not by healthy individuals 
with a record of tick bites [14]. The characterization of 
tick proteins involved in AGS and the immune mecha-
nisms triggering this syndrome is essential to answer the 
question of why only some individuals develop the AGS 
in response to tick bites [36–38] (Additional file  1: Fig-
ure S1). Tick sialome and alphagalactome profiles prob-
ably change as tick feeding proceeds thus highlighting the 
importance of the characterization of proteome changes 
during tick stages on the host to provide information on 
the abundance and risks associated with these proteins 
at different tick feeding stages. Furthermore, tick pro-
teins present in the tick sialome and reacting with IgE in 
patients but not control sera could be used for the diag-
nosis of a predisposing condition for AGS. Tick sialome 
proteins with α-Gal modification (alphagalactome) and 
recognized by patients but not sera from healthy individ-
uals exposed to tick bites could be selected as candidate 
protective antigens for the treatment and prevention of 
the AGS.
Risk factors associated to AGS may include genetic/
immune mechanisms such as atopy, and ABO blood 
group composition leading to strong IgE response against 
α-Gal after tick bite, and ecological components associ-
ated to exposure to tick bites [9, 37, 39–44]. Other fac-
tors such as alcohol consumption, physical exercise, cat 
ownership and infection with pet-associated endopara-
sites, age and use of some medications may also influence 
the risk of developing the AGS [37, 42]. A conjunction 
of these and other still unknown factors may affect the 
development of AGS by some individuals exposed to tick 
bites.
Can we benefit from the risk of developing 
the AGS?
Tick-host-pathogen interactions evolved as a conflict 
and cooperation [45]. In this context, the AGS evolved as 
a trade-off to benefit humans by providing immunity to 
pathogens containing α-Gal while increasing the risks to 
develop this syndrome [12, 39] (Additional file 1: Figure 
S1).
Some of the major infectious diseases world-
wide are caused by pathogens such as Plasmodium, 
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Mycobacterium, Trypanosoma, Borrelia and Leishmania 
species with a common characteristic of having α-Gal 
on their surface [39, 46–52]. As proposed for viruses 
with envelope-exposed α-Gal as the major evolutionary 
driver for the lack of functional GalT for α-Gal synthesis 
in humans, the possibility of developing protective anti-
bodies against this carbohydrate resulted in an effective 
protection against pathogens with α-Gal [12]. This evo-
lutionary advantage of humans relays on anti-α-Gal IgM 
and IgG antibodies produced in response to gut bacterial 
microbiota, tick infestations and/or pathogen infection 
with a protective effect against some infectious diseases 
[46–52]. However, this evolutionary cooperation between 
ticks and humans also leads to the conflict of increasing 
the risks for developing AGS in response to tick bites.
As previously proposed, we may benefit from this tick-
host conflict and cooperation [46, 47] (Additional file 1: 
Figure S1). Gut bacteria with high α-Gal content selected 
from individuals with protective immune response 
against pathogens with α-Gal could be used to develop a 
probiotic-based easy to administer and low-cost vaccine 
that could by administered by different routes alone or in 
combination with α-Gal-containing tick proteins to pro-
vide protection against multiple pathogens causing major 
infectious diseases worldwide [46, 47]. If proven true, this 
would be a major advance in the control of infectious dis-
eases affecting populations in different parts of the world.
Conclusions
The AGS has been associated with tick bites and consti-
tutes a growingly diagnosed disease worldwide. Never-
theless, many questions remain to be elucidated on the 
tick proteins and immune mechanisms triggering this 
syndrome, and the protective response against patho-
gen infection elicited by anti-α-Gal antibodies. Future 
research should focus at the identification of tick proteins 
involved in the production of anti-α-Gal IgE antibod-
ies after tick bite, and the immune mechanisms leading 
to AGS. The relationship between different tick species/
developmental stages and the AGS applying Koch’s pos-
tulates in GalT negative animal models would contribute 
to a better understanding of the disease and the evalua-
tion of epidemiological risks. Data on blood group type 
should be included in epidemiological studies to better 
evaluate the risks for AGS associated with blood type in 
the population, and the putative role of anti-α-Gal IgM 
and IgG antibodies in protection against pathogens with 
α-Gal. Other factors that may affect the AGS such as 
endoparasite infections and microbiota composition in 
both humans and ticks should be considered. The answer 
to these questions will provide information for the evalu-
ation of risks, diagnosis and prevention of the AGS, and 
the possibility of using the carbohydrate α-Gal to develop 
vaccines for the control of major infectious diseases.
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